8-K: RAPT RPT904 Shows Promising Phase 2 CSU Results

RAPT Therapeutics and Jeyou announced positive topline Phase 2 data for RPT904 in chronic spontaneous urticaria, showing comparable efficacy and safety to omalizumab with less frequent dosing.

Summary

• RAPT Therapeutics and Shanghai Jeyou Pharmaceutical announced positive topline data from Jeyou's Phase 2 trial of RPT904 (JYB1904) as monotherapy in chronic spontaneous urticaria (CSU).
• The trial, conducted in China, evaluated RPT904 at 8-week (Q8W) and 12-week (Q12W) dosing intervals against omalizumab dosed every 4 weeks (Q4W).
• RPT904 dosed Q8W or Q12W demonstrated comparable efficacy and safety to omalizumab Q4W.
• Both RPT904 arms showed numerically greater improvement in the seven-day urticaria activity score (UAS7) and a numerically higher proportion of patients achieving UAS7=0 (complete response) at Weeks 8, 12, and 16 compared to omalizumab.
• For example, at Week 16, RPT904 Q8W showed a mean UAS7 change from baseline of -23.20 (95% CI: -26.49, -19.91) and 45.65% (95% CI: 30.90, 60.99) of patients with UAS7=0, while omalizumab Q4W showed -19.14 (95% CI: -22.43, -15.86) and 33.33% (95% CI: 20.00, 48.95) of patients with UAS7=0.
• RPT904 was well tolerated, with no serious adverse events related to the study drug and no treatment-related adverse events leading to discontinuation.
• The companies believe these results support advancing RPT904 to Phase 3 development for CSU.
• RAPT also plans to initiate a Phase 2b clinical trial of RPT904 in food allergies before the end of 2025, with topline data expected in the first half of 2027.

Sentiment

Score: 8

Explanation: The positive topline Phase 2 results for RPT904 in CSU, demonstrating comparable efficacy and safety to the standard of care (omalizumab) with less frequent dosing, are highly encouraging. The potential for a 'best-in-class' profile and plans to advance to Phase 3, along with the initiation of a food allergy trial, indicate strong progress and future potential, despite the lack of statistical significance in the head-to-head comparison.

Positives

• RPT904 demonstrated comparable efficacy and safety to omalizumab, the current standard of care, in chronic spontaneous urticaria.
• RPT904 showed numerically superior efficacy on the UAS7 endpoint and a higher proportion of patients with UAS7=0 (complete response) across all measured timepoints (Weeks 8, 12, 16) compared to omalizumab.
• The drug was well tolerated, with no serious adverse events related to the study drug and no treatment-related adverse events resulting in discontinuation.
• RPT904 offers potential advantages over omalizumab, including greater durability and more convenient dosing (Q8W or Q12W vs. Q4W), which could lead to improved patient compliance and clinical outcomes.
• The positive Phase 2 results warrant advancing RPT904 to pivotal Phase 3 studies in CSU.
• RAPT anticipates initiating a Phase 2b clinical trial for RPT904 in food allergies before the end of 2025, expanding its potential indications.

Negatives

• The Phase 2 trial was not a formal non-inferiority study, and no statistical hypothesis was tested, meaning the 'numerically greater' efficacy observed for RPT904 over omalizumab is not statistically proven.
• The trial was conducted in China, and results may not be directly generalizable to other populations or regulatory environments without further studies.
• The filing does not provide specific financial projections or impacts related to the trial results.

Risks

• Unexpected or unfavorable safety or efficacy data may be observed during future clinical studies.
• Preliminary data and trends from the Phase 2 trial may not be predictive of future data or results, or may not demonstrate sufficient safety or efficacy to lead to regulatory approval.
• Reliance on partners and other third parties (like Jeyou) introduces risks regarding clinical trial execution and regulatory interactions.
• Clinical trial site activation or enrollment rates may be lower than expected, causing delays.
• Macroeconomic and geopolitical conditions (e.g., ongoing overseas conflicts, tariffs, inflation, interest rates) could cause unanticipated impacts or delays.
• Changes in expected or existing competition could affect RPT904's market potential.
• Changes in the regulatory environment and uncertainties/timing of the regulatory approval process pose risks.
• The sufficiency of the company's cash resources to fund ongoing and future development is a risk factor.

Future Outlook

RAPT Therapeutics and Jeyou plan to advance RPT904 to Phase 3 development for chronic spontaneous urticaria (CSU) and will discuss next steps with the U.S. Food and Drug Administration and other regulatory authorities. RAPT also anticipates initiating a Phase 2b clinical trial of RPT904 in food allergies before the end of 2025, with topline data expected in the first half of 2027. The company believes RPT904 has the potential for a best-in-class profile across multiple indications due to its extended half-life and durable clinical benefit.

Management Comments

• The Company and Jeyou believe these results warrant advancing RPT904 to phase 3 development.
• The Company plans to discuss next steps regarding development of RPT904 for CSU with the U.S. Food and Drug Administration and other regulatory authorities.
• Results from this randomized double-blind phase 2 study show that extended half life and pharmacodynamic effects of RPT904 translate to durable clinical benefit. (Dr. Ana Maria Giménez-Arnau)
• A single 300 mg dose of RPT904 showed numerically superior efficacy to four 300 mg doses of omalizumab at week 16*. (Dr. Ana Maria Giménez-Arnau)
• Data support promise of best-in-class profile across multiple indications. (Dr. Ana Maria Giménez-Arnau)

Industry Context

The announcement positions RPT904 as a potential competitor to omalizumab (Xolair), the current standard of care for chronic spontaneous urticaria (CSU). RPT904, as a next-generation anti-IgE antibody, aims to offer improved drug-like properties, higher potency, and a longer half-life, potentially enabling less frequent and more convenient dosing (Q8W or Q12W vs. Q4W for omalizumab). This could address a significant patient need for more convenient and potentially more effective treatment options in the CSU market, which is currently dominated by omalizumab and has other emerging therapies like remibrutinib, dupilumab, and barzolvolimab. The market research cited suggests these advantages could make RPT904 a preferred treatment option.

Comparison to Industry Standards

• RPT904 (300 mg Q8W or Q12W) demonstrated comparable efficacy and safety to omalizumab (300 mg Q4W) in the Phase 2 CSU trial.
• RPT904 showed numerically greater improvement in UAS7 scores and a higher proportion of patients achieving UAS7=0 (complete response) at Weeks 8, 12, and 16 compared to omalizumab. For instance, at Week 16, RPT904 Q8W had a mean UAS7 change of -23.20 and 45.65% UAS7=0, while omalizumab Q4W had -19.14 and 33.33% UAS7=0.
• The filing highlights RPT904's potential advantages over omalizumab, including a longer half-life, higher potency, and improved drug-like properties, which could translate to greater durability and more convenient dosing (Q8W or Q12W versus omalizumab's Q4W).
• The presentation also briefly references other CSU treatments like remibrutinib, dupilumab, rilzabrutinib, and barzolvolimab, showing their placebo-adjusted UAS7 change from baseline at Week 12, but explicitly states 'Results not from head-to-head trials; no direct comparisons can be made.'

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results, potential for a new drug in a significant market, and pipeline expansion, which could increase company valuation.
• Patients (CSU): Potential for a new, more convenient, and potentially more effective treatment option with less frequent dosing compared to current standard of care.
• Patients (Food Allergy): Future potential for a new treatment option if the Phase 2b trial is successful.
• Regulatory Authorities: Will engage in discussions regarding the registrational path for RPT904 in CSU.
• Partners (Jeyou): Strengthened partnership and potential for future commercial success in China.

Next Steps

• Advance RPT904 to Phase 3 development for chronic spontaneous urticaria (CSU).
• Discuss next steps regarding RPT904 development for CSU with the U.S. Food and Drug Administration (FDA) and other regulatory authorities.
• Initiate a Phase 2b clinical trial of RPT904 in food allergies before the end of 2025.
• Present additional efficacy and safety data from the CSU Phase 2 trial at future medical conferences.
• Expect topline data from the food allergy Phase 2b trial in 1H 2027.

Key Dates

Recommendation

The positive Phase 2 topline data for RPT904 in chronic spontaneous urticaria, showing comparable efficacy and safety to omalizumab with a significantly more convenient dosing schedule (Q8W/Q12W vs. Q4W), represents a major de-risking event and a strong competitive advantage. While the trial was not a formal non-inferiority study, the numerically superior efficacy observed, combined with a clean safety profile, strongly supports advancement to pivotal Phase 3 studies. The potential for RPT904 to be a 'best-in-class' therapy, coupled with the expansion into food allergies, indicates substantial market opportunity and pipeline growth. This news is highly positive and suggests significant upside potential for the stock, warranting a 'strong buy' recommendation for investors seeking exposure to innovative immunology therapies.

Keywords

RPT904, Chronic Spontaneous Urticaria, CSU, Omalizumab, Phase 2 Trial, Biotechnology, Pharmaceuticals, Clinical Data, IgE Antibody, Food Allergy, RAPT Therapeutics, Jeyou Pharmaceutical